Class II recall: Apollo Care, LLC: SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose

The FDA has designated a Class II recall for Apollo Care, LLC's compounded semaglutide 2.5mg (1mg/mL) with glycine 12.5mg (5mg/mL), 2.5 mL sterile multi-dose vials (NDC 71170-711-02), intended for subcutaneous injection. According to the recall notice, the action was prompted by the presence of particulate matter identified as nylon/polyamide and silk/proteinaceous-type material in the product.'

Most relevant for: Patients with obesity or type 2 diabetes who have received compounded semaglutide injections from Apollo Care, LLC

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.